Pharmacology

Action Mechanism of Action Reference
AGONIST Melanocortin receptor 2 agonist IUPHAR FDA

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Nephrotic Syndrome 3 D009404 ClinicalTrials
Neuroblastoma 3 D009447 ClinicalTrials
Arthritis, Rheumatoid 3 D001172 ClinicalTrials
Nephrotic Syndrome 3 D009404 ClinicalTrials
Arthritis, Rheumatoid 3 D001172 ClinicalTrials
Multiple Sclerosis 3 D009103 ClinicalTrials
Multiple Sclerosis, Relapsing-Remitting 3 D020529 ClinicalTrials
Multiple Sclerosis, Relapsing-Remitting 3 D020529 ClinicalTrials
Neuroblastoma 3 D009447 ClinicalTrials
Epilepsy 2 D004827 ClinicalTrials
Multiple Sclerosis, Chronic Progressive 2 D020528 ClinicalTrials
Diabetic Nephropathies 2 D003928 ClinicalTrials
Amyotrophic Lateral Sclerosis 2 D000690 ClinicalTrials
Amyotrophic Lateral Sclerosis 2 D000690 ClinicalTrials
Diabetic Nephropathies 2 D003928 ClinicalTrials
Migraine Disorders 2 D008881 ClinicalTrials
Sarcoidosis 2 D012507 ClinicalTrials
Sarcoidosis 2 D012507 ClinicalTrials
Uveitis 2 D014605 ClinicalTrials
Uveitis 2 D014605 ClinicalTrials
Dermatomyositis 2 D003882 ClinicalTrials
Dermatomyositis 2 D003882 ClinicalTrials
Epilepsy 2 D004827 ClinicalTrials
Multiple Sclerosis, Chronic Progressive 2 D020528 ClinicalTrials
Migraine Disorders 2 D008881 ClinicalTrials
Multiple Sclerosis, Chronic Progressive 2 D020528 ClinicalTrials
Multiple Sclerosis, Chronic Progressive 2 D020528 ClinicalTrials
Scleritis 2 D015423 ClinicalTrials
Scleritis 2 D015423 ClinicalTrials
Glomerulonephritis 1 D005921 ClinicalTrials
Glomerulonephritis 1 D005921 ClinicalTrials
Renal Insufficiency, Chronic 1 D051436 ClinicalTrials
Renal Insufficiency, Chronic 1 D051436 ClinicalTrials
Glomerulonephritis, Membranous 1 D015433 ClinicalTrials
Glomerulonephritis, Membranous 1 D015433 ClinicalTrials
Polycystic Ovary Syndrome 0 D011085 ClinicalTrials
Vitreoretinopathy, Proliferative 0 D018630 ClinicalTrials
Polycystic Ovary Syndrome 0 D011085 ClinicalTrials
Optic Neuritis 0 D009902 ClinicalTrials
Optic Neuritis 0 D009902 ClinicalTrials
Vitreoretinopathy, Proliferative 0 D018630 ClinicalTrials

Adverse Reactions

System Organ Classification (SOC)
Relative Frequency (%)
General disorders and administration site conditions
17.05
Nervous system disorders
9.19
Injury, poisoning and procedural complications
7.49
Skin and subcutaneous tissue disorders
6.8
Musculoskeletal and connective tissue disorders
6.73
Investigations
6.19
Respiratory, thoracic and mediastinal disorders
5.87
Vascular disorders
5.67
Psychiatric disorders
5.65
Gastrointestinal disorders
5.04
Cardiac disorders
4.84
Infections and infestations
4.16
Metabolism and nutrition disorders
4.13
Renal and urinary disorders
2.69
Immune system disorders
2.48
Eye disorders
2.07

Cross References

Resources Reference
CAS NUMBER 12427-33-7
ChEMBL CHEMBL1201610
FDA SRS K0U68Q2TXA
PubChem 16132265